Related Experiment Video
Updated: Jul 1, 2025
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
RNA Interference-based Therapies for the Reduction of Cardiovascular Risk
Natalia Nazarenko1, Jiyoung Seo1, Sanjana Nagraj2
1Jacobi Medical Center/Albert Einstein College of Medicine, 1400 Pelham Parkway S, The Bronx, NY 10461, USA.
Insights
Lowering low-density lipoprotein cholesterol (LDL-C) is crucial for reducing cardiovascular disease (CVD) risk. While effective, LDL-C reduction alone may not entirely prevent major cardiovascular events.
Area of Science:
- Cardiology
- Public Health
- Metabolic Disorders
Background:
- Cardiovascular disease (CVD) incidence is rising globally, reaching 523 million cases in 2019.
- Dyslipidemia, characterized by abnormal lipid levels, is a significant modifiable risk factor for heart disease, influenced by genetics and lifestyle.
- Lowering low-density lipoprotein cholesterol (LDL-C) is a primary strategy for CVD risk reduction.
Purpose of the Study:
- To emphasize the importance of LDL-C reduction in managing cardiovascular disease.
- To highlight the benefits of lowering LDL-C levels on coronary artery disease (CAD) and mortality.
- To acknowledge the limitations of LDL-C reduction in completely eliminating cardiovascular event risk.
Main Methods:
- Review of epidemiological data on CVD incidence trends.
- Analysis of studies investigating the impact of lipid-lowering strategies.
- Examination of the relationship between LDL-C reduction and clinical outcomes, including CAD and mortality.
Main Results:
- A 20 mg/dl reduction in LDL-C levels is associated with preventing 2-3 cases of CAD per 1000 individuals.
- Reductions in LDL-C levels demonstrate a significant mortality benefit.
- Despite benefits, LDL-C reduction does not eliminate the risk of all significant cardiovascular events.
Conclusions:
- Targeting and reducing LDL-C levels remain a cornerstone in the prevention and management of cardiovascular disease.
- Further strategies may be necessary to address residual cardiovascular risk in patients with dyslipidemia.
- The global increase in CVD underscores the need for continued research and effective interventions.
Abstract:
Globally, there remains an unwavering increase in the incidence of cvd - from 271 million in 1990 to 523 million in 2019. Among the several modifiable and non-modifiable risk factors of heart disease, dyslipidemia is an important and prevalent risk factor mediated by both genetics and lifestyle factors. Hence, lowering lipid levels, specifically, ldl-c levels (low-density lipoprotein cholesterol), is a key strategy in decreasing the risk of cardiovascular disease. A reduction of 20 mg/dl in ldl-c levels has been found to prevent 2-3 cases of coronary artery disease (cad) for every 1000 individuals. Studies have also found reductions in ldl-c levels to be associated with a mortality benefit. However, ldl-c levels reduction may not eliminate the risk of significant cardiovascular events.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
02:15Experimental RNAi